Free Trial
→ White House to reset Social Security? (From Altimetry) (Ad) Buy NEO Stock  Free NEO Stock Alerts

NeoGenomics (NEO) Financials

NeoGenomics logo
$7.42 -0.08 (-1.07%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$7.56 +0.14 (+1.82%)
As of 05/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for NeoGenomics

Annual Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 -79 -88 -144 -8.35 4.17 8.01 6.09 -11 -31 -2.66 1.13
Consolidated Net Income / (Loss)		 -79 -88 -144 -8.35 4.17 8.01 2.64 -0.40 -6.14 -2.54 1.13
Net Income / (Loss) Continuing Operations		 -79 -88 -144 -8.35 4.17 8.01 2.64 -0.40 -6.14 -2.54 1.13
Total Pre-Tax Income 		-81 -97 -159 -15 -14 3.65 3.82 -2.65 -7.84 -4.49 1.29
Total Operating Income		 -92 -108 -158 -119 -14 13 10 2.90 2.16 -5.64 2.22
Total Gross Profit		 290 245 188 187 186 197 127 102 98 44 41
Total Revenue		 661 592 510 484 444 409 277 240 232 100 87
Operating Revenue		 661 592 510 484 444 409 277 240 232 100 87
Total Cost of Revenue		 370 347 322 297 259 212 149 138 134 56 46
Operating Cost of Revenue		 370 347 322 297 259 212 149 138 134 56 46
Total Operating Expenses		 382 352 346 306 200 184 117 99 96 49 38
Selling, General & Admin Expense		 260 243 243 221 144 128 85 70 64 34 24
Marketing Expense		 85 71 67 63 48 47 29 24 24 12 12
Research & Development Expense		 31 27 30 22 8.23 8.49 3.00 3.64 4.65 4.20 2.69
Restructuring Charge		 6.66 11 4.52 0.00 0.00 - - - - - -
Total Other Income / (Expense), net		 11 11 -1.72 104 -0.06 -9.36 -6.22 -5.55 -10.00 1.15 -0.93
Interest Expense		 6.62 6.91 7.58 8.22 12 4.73 6.23 5.54 10.00 0.85 0.99
Interest & Investment Income		 18 17 6.08 3.14 - - - - - - -
Other Income / (Expense), net		 -0.38 0.64 -0.21 109 12 -4.63 0.01 -0.01 0.00 2.00 0.06
Income Tax Expense		 -1.95 -9.13 -15 -6.73 -18 -4.36 1.18 -2.25 -1.70 -1.95 0.16
Basic Earnings per Share		 ($0.62) ($0.70) ($1.16) - - $0.08 $0.07 ($0.14) ($0.40) ($0.04) $0.02
Weighted Average Basic Shares Outstanding		 126.66M 125.50M 124.22M 119.96M 108.58M 100.47M 85.62M 79.43M 77.54M 60.53M 53.48M
Diluted Earnings per Share		 ($0.62) ($0.70) ($1.16) - - $0.08 $0.07 ($0.14) ($0.40) ($0.04) $0.02
Weighted Average Diluted Shares Outstanding		 126.66M 125.50M 124.22M 119.96M 111.79M 103.62M 91.57M 79.43M 77.54M 60.53M 56.02M
Weighted Average Basic & Diluted Shares Outstanding		 128.46M 127.61M 127.46M 124.03M 116.94M 104.83M 94.57M 80.51M 78.82M 66.40M 56.60M

Quarterly Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -26 -15 -18 -19 -27 -14 -19 -24 -31 -23 -37
Consolidated Net Income / (Loss)		 -26 -15 -18 -19 -27 -14 -19 -24 -31 -23 -37
Net Income / (Loss) Continuing Operations		 -26 -15 -18 -19 -27 -14 -19 -24 -31 -23 -37
Total Pre-Tax Income 		-26 -16 -18 -19 -28 -15 -21 -27 -34 -26 -40
Total Operating Income		 -28 -18 -21 -22 -31 -19 -24 -30 -35 -26 -40
Total Gross Profit		 73 77 75 72 65 68 62 60 55 57 49
Total Revenue		 168 172 168 165 156 156 152 147 137 139 129
Operating Revenue		 168 172 168 165 156 156 152 147 137 139 129
Total Cost of Revenue		 95 95 93 92 91 88 90 87 82 82 80
Operating Cost of Revenue		 95 95 93 92 91 88 90 87 82 82 80
Total Operating Expenses		 101 96 96 94 96 86 87 90 90 83 88
Selling, General & Admin Expense		 68 64 67 63 66 60 61 60 62 55 64
Marketing Expense		 23 22 20 22 20 18 18 19 16 17 17
Research & Development Expense		 10 7.97 7.68 7.89 7.62 7.13 5.29 7.50 7.40 6.68 7.31
Restructuring Charge		 0.00 1.71 1.01 1.54 2.40 1.21 2.13 3.07 4.68 4.52 0.00
Total Other Income / (Expense), net		 2.17 2.27 3.35 2.92 2.89 3.29 2.74 3.25 1.35 0.86 -0.11
Interest Expense		 1.62 1.62 1.64 1.67 1.69 1.68 1.69 1.78 1.76 5.22 0.14
Interest & Investment Income		 3.72 4.33 4.67 4.59 4.83 4.85 4.53 4.31 3.22 - -
Other Income / (Expense), net		 0.07 -0.43 0.32 -0.00 -0.26 0.12 -0.10 0.73 -0.11 -0.00 0.03
Income Tax Expense		 0.27 -0.80 -0.15 -0.38 -0.62 -0.96 -2.94 -2.31 -2.93 -2.84 -2.77
Basic Earnings per Share		 ($0.20) - ($0.14) - ($0.21) - ($0.15) - ($0.25) ($0.18) ($0.30)
Weighted Average Basic Shares Outstanding		 127.38M 126.66M 126.95M 126.41M 126.11M 125.50M 125.69M 125.36M 125.03M 124.22M 124.43M
Diluted Earnings per Share		 ($0.20) - ($0.14) - ($0.21) - ($0.15) - ($0.25) ($0.18) ($0.30)
Weighted Average Diluted Shares Outstanding		 127.38M 126.66M 126.95M 126.41M 126.11M 125.50M 125.69M 125.36M 125.03M 124.22M 124.43M
Weighted Average Basic & Diluted Shares Outstanding		 128.69M 128.46M 128.36M 128.16M 127.71M 127.61M 127.47M 127.55M 127.58M 127.46M 126.30M

Annual Cash Flow Statements for NeoGenomics

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 25 79 -54 66 78 163 -3.01 0.30 -11 -10 29
Net Cash From Operating Activities		 7.02 -1.95 -66 -27 1.46 23 45 18 21 6.39 9.45
Net Cash From Continuing Operating Activities		 7.02 -1.95 -66 -27 1.46 23 45 18 21 6.39 9.45
Net Income / (Loss) Continuing Operations		 -79 -88 -144 -8.35 4.17 8.01 2.64 -0.40 -6.14 -2.54 1.13
Consolidated Net Income / (Loss)		 -79 -88 -144 -8.35 4.17 8.01 2.64 -0.40 -6.14 -2.54 1.13
Depreciation Expense		 39 37 35 30 26 20 16 16 16 6.73 5.35
Amortization Expense		 36 38 37 26 14 10 6.47 7.44 11 0.41 0.36
Non-Cash Adjustments To Reconcile Net Income		 37 28 36 -84 -6.35 17 7.36 7.75 10 3.73 3.13
Changes in Operating Assets and Liabilities, net		 -26 -18 -30 10 -37 -32 13 -12 -9.09 -1.95 -0.52
Net Cash From Investing Activities		 13 77 0.52 -632 -159 -20 -140 -14 -6.50 -75 -9.60
Net Cash From Continuing Investing Activities		 13 77 0.52 -632 -159 -20 -140 -14 -6.50 -75 -9.60
Purchase of Property, Plant & Equipment		 -41 -29 -31 -64 -29 -20 -14 -14 -7.54 -2.22 -3.77
Purchase of Investments		 0.00 -6.76 -98 -212 -99 0.00 0.00 - - - -
Sale of Property, Plant & Equipment		 0.00 0.00 12 0.00 0.00 - - - - - -
Sale and/or Maturity of Investments		 54 112 117 63 5.36 0.00 0.00 - - - -
Net Cash From Financing Activities		 4.65 4.55 12 725 236 159 92 -4.10 -26 58 29
Net Cash From Continuing Financing Activities		 4.65 4.55 12 725 236 159 92 -4.10 -26 58 29
Issuance of Common Equity		 4.65 4.62 13 15 20 11 9.02 2.59 3.77 0.94 37
Other Financing Activities, net		 0.00 -0.07 -0.76 -32 -8.93 -7.20 -6.56 -5.42 - - -
Cash Interest Paid		 3.83 3.38 3.40 3.07 2.93 4.78 6.51 5.16 5.42 0.91 0.98
Cash Income Taxes Paid		 0.21 0.18 0.18 0.15 0.25 0.32 -0.03 0.28 0.29 0.03 0.18

Quarterly Cash Flow Statements for NeoGenomics

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -21 5.02 6.91 23 -11 36 17 13 12 -2.95 -18
Net Cash From Operating Activities		 -25 9.80 9.25 14 -26 18 -5.50 -1.55 -13 -3.69 -16
Net Cash From Continuing Operating Activities		 -25 9.80 9.25 14 -26 18 -5.50 -1.55 -13 -3.69 -16
Net Income / (Loss) Continuing Operations		 -26 -15 -18 -19 -27 -14 -19 -24 -31 -23 -37
Consolidated Net Income / (Loss)		 -26 -15 -18 -19 -27 -14 -19 -24 -31 -23 -37
Depreciation Expense		 9.37 9.83 9.62 9.75 9.91 9.58 9.35 9.48 9.05 9.48 8.97
Amortization Expense		 9.10 9.09 9.09 9.09 9.09 9.51 9.51 9.50 9.50 9.30 9.20
Non-Cash Adjustments To Reconcile Net Income		 11 8.53 6.48 13 8.89 1.70 13 7.19 6.29 15 7.58
Changes in Operating Assets and Liabilities, net		 -29 -2.32 1.76 0.85 -27 11 -19 -3.38 -6.73 -14 -5.17
Net Cash From Investing Activities		 3.56 -5.47 -3.52 7.31 15 17 21 15 24 -1.06 -4.20
Net Cash From Continuing Investing Activities		 3.56 -5.47 -3.52 7.31 15 17 21 15 24 -1.06 -4.20
Purchase of Property, Plant & Equipment		 -4.50 -12 -11 -13 -5.59 -7.06 -4.27 -7.49 -9.93 -4.53 -7.84
Sale and/or Maturity of Investments		 8.06 6.13 7.28 20 20 24 25 22 40 27 21
Net Cash From Financing Activities		 0.95 0.69 1.18 1.97 0.82 1.27 1.84 0.06 1.38 1.80 2.96
Net Cash From Continuing Financing Activities		 0.95 0.69 1.18 1.97 0.82 1.27 1.84 0.06 1.38 1.80 2.96
Issuance of Common Equity		 0.95 0.69 1.18 1.97 0.82 1.27 1.85 0.09 1.41 1.85 3.09
Cash Interest Paid		 0.00 1.69 0.45 1.26 0.43 1.26 0.43 1.26 0.43 1.26 0.00
Cash Income Taxes Paid		 0.00 -0.11 0.14 0.09 0.09 - - 0.18 0.00 0.03 0.03

Annual Balance Sheets for NeoGenomics

This table presents NeoGenomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 1,638 1,681 1,740 1,870 988 710 505 344 337 351 81
Total Current Assets		 596 597 605 682 449 291 104 86 79 82 59
Cash & Equivalents		 367 342 263 317 229 173 9.81 13 13 23 34
Short-Term Investments		 20 73 175 - 68 0.00 - - - - -
Accounts Receivable		 151 131 120 112 107 94 77 60 56 49 20
Inventories, net		 27 24 24 23 30 14 8.65 7.47 6.25 5.11 2.62
Prepaid Expenses		 20 18 15 12 12 6.33 7.73 4.15 4.54 4.89 1.14
Other Current Assets		 12 8.24 8.08 18 4.56 2.75 0.56 1.00 - - -
Plant, Property, & Equipment, net		 94 92 102 109 86 64 61 37 34 35 15
Total Noncurrent Assets		 948 992 1,032 1,079 454 355 340 222 224 234 7.28
Goodwill		 523 523 523 527 211 199 198 147 147 146 2.93
Intangible Assets		 340 373 408 442 121 127 140 74 77 88 4.21
Other Noncurrent Operating Assets		 85 97 101 109 92 29 2.54 0.89 0.17 0.13 0.14
Total Liabilities & Shareholders' Equity		 1,638 1,681 1,740 1,870 988 710 505 344 337 351 81
Total Liabilities		 736 740 742 762 294 202 185 140 151 113 21
Total Current Liabilities		 301 96 90 87 73 64 61 36 38 40 15
Short-Term Debt		 201 0.00 - - - 5.00 7.87 8.99 8.73 14 3.22
Accounts Payable		 22 20 21 18 25 20 18 10 17 12 6.29
Accrued Expenses		 13 15 15 18 12 7.55 8.99 6.14 4.25 7.37 1.21
Current Deferred Revenue		 0.41 2.13 7.56 5.19 4.03 1.61 - - - - -
Current Employee Benefit Liabilities		 62 53 40 38 25 21 19 9.48 8.35 6.22 3.90
Other Current Liabilities		 3.38 5.61 6.65 8.02 7.81 8.81 7.23 1.41 - - 0.00
Total Noncurrent Liabilities		 434 643 652 674 221 138 124 103 112 73 6.08
Long-Term Debt		 340 538 535 532 168 92 98 91 92 52 0.06
Noncurrent Deferred & Payable Income Tax Liabilities		 22 24 35 55 5.42 16 22 6.69 15 16 0.82
Other Noncurrent Operating Liabilities		 73 81 82 86 47 31 3.06 0.28 - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 902 942 998 1,108 694 507 320 172 164 210 60
Total Preferred & Common Equity		 902 942 998 1,108 694 507 320 172 164 210 60
Total Common Equity		 902 942 998 1,108 694 507 320 172 164 210 60
Common Stock		 1,228 1,190 1,161 1,124 701 520 340 230 216 232 80
Retained Earnings		 -326 -247 -159 -15 -7.19 -11 -19 -58 -52 -22 -19
Accumulated Other Comprehensive Income / (Loss)		 -0.21 -1.67 -3.90 -0.64 0.01 -1.62 -0.58 0.27 0.00 - -

Quarterly Balance Sheets for NeoGenomics

This table presents NeoGenomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,601 1,641 1,643 1,640 1,678 1,695 1,709 1,756
Total Current Assets		 574 590 584 574 587 585 585 603
Cash & Equivalents		 346 362 355 332 306 289 276 266
Short-Term Investments		 12 26 33 53 96 120 142 177
Accounts Receivable		 151 151 147 140 133 125 119 112
Inventories, net		 30 24 23 20 24 25 24 24
Prepaid Expenses		 23 18 17 19 19 17 16 17
Other Current Assets		 12 8.31 9.16 9.31 9.32 8.43 7.62 7.52
Plant, Property, & Equipment, net		 90 93 92 88 95 100 103 107
Total Noncurrent Assets		 938 958 967 979 997 1,010 1,021 1,045
Goodwill		 523 523 523 523 523 523 523 523
Intangible Assets		 331 348 356 365 382 391 399 417
Other Noncurrent Operating Assets		 84 87 88 91 92 97 99 106
Total Liabilities & Shareholders' Equity		 1,601 1,641 1,643 1,640 1,678 1,695 1,709 1,756
Total Liabilities		 713 733 727 717 731 739 735 743
Total Current Liabilities		 280 296 290 77 93 95 87 85
Short-Term Debt		 201 200 200 - - - - -
Accounts Payable		 16 17 17 18 17 18 23 14
Accrued Expenses		 19 23 17 18 19 18 18 20
Current Deferred Revenue		 1.16 0.59 0.97 1.14 3.62 5.71 6.07 6.39
Current Employee Benefit Liabilities		 39 52 51 35 48 46 33 38
Other Current Liabilities		 3.08 3.72 3.57 4.49 6.22 7.37 6.97 6.50
Total Noncurrent Liabilities		 433 436 437 640 638 644 648 658
Long-Term Debt		 341 340 340 539 537 537 536 535
Noncurrent Deferred & Payable Income Tax Liabilities		 21 23 23 23 25 29 32 38
Other Noncurrent Operating Liabilities		 72 74 75 78 75 79 80 85
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 888 908 916 923 947 956 974 1,013
Total Preferred & Common Equity		 888 908 916 923 947 956 974 1,013
Total Common Equity		 888 908 916 923 947 956 974 1,013
Common Stock		 1,240 1,219 1,210 1,199 1,182 1,173 1,167 1,154
Retained Earnings		 -352 -310 -293 -274 -233 -214 -190 -136
Accumulated Other Comprehensive Income / (Loss)		 -0.06 -0.64 -1.02 -1.33 -1.85 -2.57 -2.83 -5.10

Annual Metrics And Ratios for NeoGenomics

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.65% 16.07% 5.24% 8.97% 8.71% 47.73% 15.19% 3.64% 132.27% 14.62% 31.00%
EBITDA Growth		 46.18% 63.03% -285.61% 20.96% -2.37% 20.75% 24.72% -10.19% 722.95% -56.05% 4.52%
EBIT Growth		 13.64% 32.15% -1,479.47% -368.93% -125.44% -16.69% 247.89% 34.11% 159.28% -259.85% -28.36%
NOPAT Growth		 14.51% 31.65% -32.73% -748.73% -134.29% 312.14% 241.21% 34.66% 138.24% -302.51% -34.04%
Net Income Growth		 10.51% 39.02% -1,628.17% -300.07% -47.89% 203.26% 766.67% 93.55% -142.29% -323.94% -44.32%
EPS Growth		 11.43% 39.66% 0.00% 0.00% 0.00% 14.29% 150.00% 65.00% -900.00% -300.00% -50.00%
Operating Cash Flow Growth		 459.60% 97.04% -146.95% -1,930.34% -93.75% -47.82% 148.30% -16.02% 235.95% -32.35% 324.34%
Free Cash Flow Firm Growth		 -26.82% 44.48% 88.05% -483.38% -923.80% 112.42% -654.76% -303.13% 102.88% -4,139.80% -89.55%
Invested Capital Growth		 -0.74% -2.81% -2.67% 109.72% 24.44% 3.50% 40.20% 6.04% -2.04% 712.77% 29.22%
Revenue Q/Q Growth		 2.55% 2.93% 2.61% -0.05% 4.50% 8.03% 5.75% 5.82% 9.93% 2.34% 8.31%
EBITDA Q/Q Growth		 -3.31% 20.66% 16.84% -51.78% 58.75% 3.87% -1.34% 16.33% 46.37% -54.19% 7.13%
EBIT Q/Q Growth		 -0.41% 6.90% 9.26% -121.83% 83.06% -0.61% -7.60% 169.50% 632.99% -503.89% 8.13%
NOPAT Q/Q Growth		 0.19% 6.76% 8.79% 12.81% 18.70% 167.80% -55.94% 169.79% 632.99% -2,354.36% 10.71%
Net Income Q/Q Growth		 -1.28% 8.68% 11.68% -117.09% 184.30% 288.08% -61.39% 96.58% -350.95% -776.00% 20.17%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 300.00% -22.22% 61.11% -66.67% -500.00% 0.00%
Operating Cash Flow Q/Q Growth		 -53.20% 91.66% 19.60% -2,677.86% 225.21% -34.10% 27.62% 49.85% -9.91% 21.59% 18.73%
Free Cash Flow Firm Q/Q Growth		 -32.33% 25.01% 18.63% 3.75% 2.60% 112.56% -979.07% 0.00% 103.03% -5,078.49% 24.10%
Invested Capital Q/Q Growth		 -0.39% -1.67% -0.79% -0.08% 2.48% 3.31% 41.02% 1.60% -0.10% 656.22% 6.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 43.92% 41.34% 36.86% 38.62% 41.83% 48.15% 45.99% 42.44% 42.32% 43.84% 46.76%
EBITDA Margin		 -2.58% -5.35% -16.79% 9.52% 8.58% 9.55% 11.68% 10.79% 12.45% 3.51% 9.17%
Operating Margin		 -13.94% -18.21% -30.92% -24.52% -3.15% 3.18% 3.63% 1.21% 0.93% -5.65% 2.55%
EBIT Margin		 -14.00% -18.10% -30.96% -2.06% -0.48% 2.05% 3.63% 1.20% 0.93% -3.64% 2.61%
Profit (Net Income) Margin		 -11.92% -14.87% -28.30% -1.72% 0.94% 1.96% 0.95% -0.16% -2.65% -2.54% 1.30%
Tax Burden Percent		 97.58% 90.60% 90.53% 55.37% -29.68% 219.64% 69.04% 14.94% 78.31% 56.47% 87.82%
Interest Burden Percent		 87.23% 90.67% 100.95% 150.86% 659.60% 43.52% 38.03% -91.70% -363.94% 123.49% 56.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% -119.64% 30.96% 0.00% 0.00% 0.00% 12.18%
Return on Invested Capital (ROIC)		 -6.08% -6.98% -9.94% -10.00% -2.02% 6.74% 1.94% 0.70% 0.53% -2.46% 6.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 -16.36% -18.38% -69.21% -116.38% -13.97% -198.82% -2.60% -1.90% -10.27% 9.94% 14.53%
Return on Net Nonoperating Assets (RNNOA)		 -2.46% -2.09% -3.76% 9.08% 2.72% -4.80% -0.94% -0.91% -3.43% 0.76% -3.48%
Return on Equity (ROE)		 -8.54% -9.07% -13.70% -0.93% 0.69% 1.93% 1.01% -0.20% -2.89% -1.70% 2.76%
Cash Return on Invested Capital (CROIC)		 -5.33% -4.13% -7.23% -80.86% -23.80% 3.30% -31.53% -5.16% 2.59% -158.63% -19.25%
Operating Return on Assets (OROA)		 -5.57% -6.26% -8.74% -0.70% -0.25% 1.38% 2.37% 0.85% 0.63% -1.68% 3.76%
Return on Assets (ROA)		 -4.74% -5.14% -7.99% -0.58% 0.49% 1.32% 0.62% -0.12% -1.78% -1.17% 1.87%
Return on Common Equity (ROCE)		 -8.54% -9.07% -13.70% -0.93% 0.69% 1.93% 0.94% -0.17% -2.54% -1.54% 2.76%
Return on Equity Simple (ROE_SIMPLE)		 -8.72% -9.34% -14.45% -0.75% 0.60% 1.58% 0.82% -0.23% -3.75% -1.21% 1.87%
Net Operating Profit after Tax (NOPAT)		 -64 -75 -110 -83 -9.79 29 6.93 2.03 1.51 -3.94 1.95
NOPAT Margin		 -9.76% -12.75% -21.65% -17.16% -2.20% 6.99% 2.50% 0.85% 0.65% -3.95% 2.24%
Net Nonoperating Expense Percent (NNEP)		 10.28% 11.39% 59.28% 106.37% 11.94% 205.56% 4.55% 2.61% 10.81% -12.39% -8.29%
Return On Investment Capital (ROIC_SIMPLE)		 -4.47% -5.10% -7.20% - - - - - - - -
Cost of Revenue to Revenue		 56.08% 58.66% 63.14% 61.38% 58.17% 51.85% 54.01% 57.56% 57.68% 56.16% 53.24%
SG&A Expenses to Revenue		 39.32% 41.09% 47.74% 45.70% 32.35% 31.31% 30.65% 29.29% 27.58% 33.70% 27.34%
R&D to Revenue		 4.72% 4.62% 5.95% 4.52% 1.85% 2.08% 1.08% 1.51% 2.01% 4.21% 3.09%
Operating Expenses to Revenue		 57.86% 59.55% 67.79% 63.14% 44.97% 44.96% 42.36% 41.23% 41.39% 49.49% 44.21%
Earnings before Interest and Taxes (EBIT)		 -92 -107 -158 -9.99 -2.13 8.38 10 2.89 2.16 -3.64 2.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -32 -86 46 38 39 32 26 29 3.51 7.98
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.34 2.19 1.17 3.79 8.61 6.02 3.66 4.14 4.11 2.27 4.14
Price to Tangible Book Value (P/TBV)		 53.03 45.19 17.42 30.26 16.49 16.76 0.00 0.00 0.00 0.00 4.70
Price to Revenue (P/Rev)		 3.20 3.49 2.29 8.67 13.45 7.47 4.24 2.97 2.90 4.76 2.87
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 1,432.85 381.45 192.66 0.00 0.00 0.00 220.92
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.07% 0.26% 0.52% 0.00% 0.00% 0.00% 0.45%
Enterprise Value to Invested Capital (EV/IC)		 2.15 2.05 1.15 3.92 10.85 6.91 3.05 2.82 2.82 1.93 6.39
Enterprise Value to Revenue (EV/Rev)		 3.44 3.69 2.48 9.12 13.10 7.28 4.59 3.49 3.41 5.53 2.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 95.80 152.71 76.28 39.26 32.32 27.35 157.26 28.18
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 355.51 126.23 289.84 366.30 0.00 98.89
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 104.24 183.10 412.35 523.28 0.00 115.45
Enterprise Value to Operating Cash Flow (EV/OCF)		 323.17 0.00 0.00 0.00 3,986.40 127.42 28.34 46.44 36.75 86.27 23.80
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 212.99 0.00 0.00 107.55 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.60 0.57 0.54 0.48 0.24 0.19 0.33 0.52 0.57 0.30 0.14
Long-Term Debt to Equity		 0.38 0.57 0.54 0.48 0.24 0.18 0.31 0.47 0.52 0.24 0.09
Financial Leverage		 0.15 0.11 0.05 -0.08 -0.19 0.02 0.36 0.48 0.33 0.08 -0.24
Leverage Ratio		 1.80 1.76 1.71 1.59 1.41 1.47 1.62 1.74 1.62 1.45 1.47
Compound Leverage Factor		 1.57 1.60 1.73 2.39 9.32 0.64 0.62 -1.60 -5.90 1.79 0.84
Debt to Total Capital		 37.49% 36.37% 34.91% 32.45% 19.49% 16.03% 24.86% 34.01% 36.26% 23.06% 12.31%
Short-Term Debt to Total Capital		 13.91% 0.00% 0.00% 0.00% 0.00% 0.83% 1.85% 2.90% 2.98% 4.52% 4.68%
Long-Term Debt to Total Capital		 23.58% 36.37% 34.91% 32.45% 19.49% 15.20% 23.01% 31.11% 33.28% 18.54% 7.63%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.52% 7.81% 9.24% 0.00%
Common Equity to Total Capital		 62.51% 63.63% 65.09% 67.55% 80.51% 83.98% 75.14% 55.47% 55.92% 67.70% 87.69%
Debt to EBITDA		 -31.79 -17.01 -6.26 11.55 4.41 2.48 3.28 4.07 3.68 20.35 1.06
Net Debt to EBITDA		 -9.06 -3.89 -1.14 4.68 -4.14 -1.95 2.98 3.57 3.24 13.68 -3.16
Long-Term Debt to EBITDA		 -19.99 -17.01 -6.26 11.55 4.41 2.35 3.04 3.72 3.38 16.36 0.66
Debt to NOPAT		 -8.39 -7.14 -4.85 -6.41 -17.16 3.39 15.29 51.90 70.38 -18.10 4.35
Net Debt to NOPAT		 -2.39 -1.63 -0.88 -2.59 16.10 -2.67 13.88 45.59 62.08 -12.16 -12.94
Long-Term Debt to NOPAT		 -5.28 -7.14 -4.85 -6.41 -17.16 3.21 14.16 47.47 64.59 -14.55 2.70
Altman Z-Score		 1.88 1.97 1.16 3.92 13.09 10.04 4.47 3.72 3.32 2.82 8.73
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.21% 14.19% 12.12% 9.58% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.98 6.20 6.73 7.81 6.13 4.55 1.70 2.35 2.07 2.06 4.02
Quick Ratio		 1.78 5.67 6.20 4.92 5.51 4.18 1.42 2.01 1.79 1.81 3.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -57 -45 -80 -672 -115 14 -113 -15 7.34 -255 -6.01
Operating Cash Flow to CapEx		 17.10% -6.79% -351.16% -41.66% 5.02% 116.68% 312.97% 131.75% 284.99% 288.62% 250.53%
Free Cash Flow to Firm to Interest Expense		 -8.55 -6.46 -10.60 -81.74 -9.66 2.96 -18.06 -2.69 0.73 -298.38 -6.10
Operating Cash Flow to Interest Expense		 1.06 -0.28 -8.71 -3.25 0.12 4.94 7.19 3.26 2.15 7.49 9.59
Operating Cash Flow Less CapEx to Interest Expense		 -5.14 -4.45 -11.18 -11.05 -2.32 0.71 4.89 0.78 1.39 4.89 5.76
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.40 0.35 0.28 0.34 0.52 0.67 0.65 0.71 0.67 0.46 1.44
Accounts Receivable Turnover		 4.69 4.72 4.40 4.42 4.42 4.78 4.03 4.14 4.44 2.88 4.45
Inventory Turnover		 14.56 14.33 13.50 11.23 11.77 18.39 18.54 20.15 23.54 14.51 18.86
Fixed Asset Turnover		 7.10 6.08 4.81 4.96 5.92 6.54 5.68 6.81 6.76 4.02 7.03
Accounts Payable Turnover		 17.67 16.99 16.75 13.86 11.61 11.35 10.59 10.16 9.14 5.98 8.85
Days Sales Outstanding (DSO)		 77.85 77.41 83.01 82.51 82.57 76.41 90.57 88.07 82.24 126.94 82.01
Days Inventory Outstanding (DIO)		 25.08 25.47 27.03 32.49 31.01 19.85 19.69 18.11 15.51 25.15 19.36
Days Payable Outstanding (DPO)		 20.66 21.48 21.79 26.33 31.43 32.15 34.47 35.94 39.92 61.08 41.22
Cash Conversion Cycle (CCC)		 82.26 81.40 88.25 88.67 82.14 64.10 75.80 70.25 57.82 91.01 60.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,057 1,065 1,095 1,125 537 431 417 297 280 286 35
Invested Capital Turnover		 0.62 0.55 0.46 0.58 0.92 0.96 0.78 0.83 0.82 0.62 2.79
Increase / (Decrease) in Invested Capital		 -7.93 -31 -30 589 105 15 119 17 -5.83 251 7.96
Enterprise Value (EV)		 2,270 2,185 1,264 4,417 5,820 2,978 1,269 838 789 552 225
Market Capitalization		 2,115 2,062 1,167 4,201 5,978 3,054 1,173 712 673 475 250
Book Value per Share		 $7.03 $7.39 $7.90 $9.00 $6.25 $4.86 $3.45 $2.14 $2.09 $3.47 $1.01
Tangible Book Value per Share		 $0.31 $0.36 $0.53 $1.13 $3.27 $1.74 ($0.19) ($0.61) ($0.77) ($0.41) $0.89
Total Capital		 1,443 1,480 1,533 1,641 862 604 426 310 293 309 69
Total Debt		 541 538 535 532 168 97 106 105 106 71 8.48
Total Long-Term Debt		 340 538 535 532 168 92 98 96 97 57 5.26
Net Debt		 154 123 97 216 -158 -76 96 93 94 48 -25
Capital Expenditures (CapEx)		 41 29 19 64 29 20 14 14 7.54 2.22 3.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 109 85 77 277 79 59 41 46 37 33 14
Debt-free Net Working Capital (DFNWC)		 496 501 515 594 376 232 51 58 49 56 47
Net Working Capital (NWC)		 295 501 515 594 376 227 43 49 41 42 44
Net Nonoperating Expense (NNE)		 14 13 34 -75 -14 21 4.29 2.43 7.65 -1.41 0.82
Net Nonoperating Obligations (NNO)		 154 123 97 17 -158 -76 96 93 94 48 -25
Total Depreciation and Amortization (D&A)		 75 75 72 56 40 31 22 23 27 7.14 5.71
Debt-free, Cash-free Net Working Capital to Revenue		 16.46% 14.42% 15.18% 57.29% 17.84% 14.39% 14.74% 18.97% 15.93% 32.95% 15.68%
Debt-free Net Working Capital to Revenue		 75.02% 84.60% 101.10% 122.70% 84.50% 56.71% 18.29% 24.31% 21.33% 56.42% 54.37%
Net Working Capital to Revenue		 44.63% 84.60% 101.10% 122.70% 84.50% 55.48% 15.45% 20.56% 17.56% 42.39% 50.67%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.62) $0.00 $0.00 ($0.07) $0.04 $0.08 $0.07 $0.00 ($0.39) $0.00 $0.02
Adjusted Weighted Average Basic Shares Outstanding		 126.66M 125.50M 124.22M 119.96M 108.58M 100.47M 85.62M 79.43M 77.54M 0.00 53.48M
Adjusted Diluted Earnings per Share		 ($0.62) $0.00 $0.00 ($0.07) $0.04 $0.08 $0.07 $0.00 ($0.39) $0.00 $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 126.66M 125.50M 124.22M 119.96M 111.79M 103.62M 91.57M 79.43M 77.54M 0.00 56.02M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 128.46M 127.61M 127.46M 124.03M 116.94M 104.83M 94.57M 80.51M 78.82M 0.00 60.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -60 -68 -107 -83 -9.79 9.10 6.93 2.03 3.93 -3.94 1.95
Normalized NOPAT Margin		 -9.05% -11.43% -21.03% -17.16% -2.20% 2.23% 2.50% 0.85% 1.70% -3.95% 2.24%
Pre Tax Income Margin		 -12.21% -16.41% -31.26% -3.11% -3.16% 0.89% 1.38% -1.10% -3.38% -4.50% 1.48%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -13.98 -15.50 -20.82 -1.22 -0.18 1.77 1.61 0.52 0.22 -4.26 2.31
NOPAT to Interest Expense		 -9.74 -10.92 -14.55 -10.11 -0.82 6.04 1.11 0.37 0.15 -4.62 1.98
EBIT Less CapEx to Interest Expense		 -20.18 -19.67 -23.30 -9.02 -2.62 -2.46 -0.68 -1.95 -0.54 -6.85 -1.52
NOPAT Less CapEx to Interest Expense		 -15.95 -15.08 -17.03 -17.92 -3.26 1.80 -1.18 -2.10 -0.60 -7.21 -1.85
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NeoGenomics

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 7.55% 10.57% 10.44% 11.97% 13.86% 12.15% 17.99% 17.47% 17.11% 10.32% 6.13%
EBITDA Growth		 21.46% -86.10% 60.18% 69.48% 28.86% 108.32% 74.49% 54.48% 51.44% 69.50% -371.48%
EBIT Growth		 9.96% -2.07% 14.04% 24.76% 12.38% 30.07% 38.48% 27.28% 32.15% 37.91% -80.51%
NOPAT Growth		 8.97% 0.93% 12.39% 26.60% 12.85% 29.60% 38.76% 24.70% 32.59% 36.53% 0.51%
Net Income Growth		 4.21% -6.97% 4.41% 23.38% 12.13% 36.85% 49.76% 31.08% 37.67% 45.67% -81.11%
EPS Growth		 4.76% 0.00% 6.67% 0.00% 16.00% 0.00% 50.00% 0.00% 37.50% 0.00% -76.47%
Operating Cash Flow Growth		 2.27% -44.89% 268.20% 997.42% -104.18% 582.61% 66.22% 90.89% 56.29% 81.37% -109.50%
Free Cash Flow Firm Growth		 -121.80% -127.81% 56.74% -91.88% -165.60% 54.36% 183.01% 121.98% 101.55% 101.87% 99.14%
Invested Capital Growth		 -0.51% -0.74% -2.02% -1.47% -1.38% -2.81% -1.94% -2.51% -3.03% -2.67% -1.98%
Revenue Q/Q Growth		 -2.31% 2.49% 2.02% 5.29% 0.44% 2.37% 3.43% 7.07% -1.07% 7.71% 2.97%
EBITDA Q/Q Growth		 -10,664.77% 104.06% 30.36% 73.74% -1,970.14% 111.64% 46.63% 38.78% -118.85% 64.32% 4.79%
EBIT Q/Q Growth		 -47.41% 9.81% 4.84% 28.83% -67.10% 24.05% 16.71% 17.12% -33.36% 33.18% 1.55%
NOPAT Q/Q Growth		 -51.21% 13.19% 3.39% 28.22% -64.57% 23.23% 19.06% 14.77% -32.94% 33.22% 0.48%
Net Income Q/Q Growth		 -69.17% 13.42% 5.06% 31.11% -88.89% 22.63% 23.90% 20.99% -35.74% 38.44% -4.39%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.00% -7.14%
Operating Cash Flow Q/Q Growth		 -358.44% 5.99% -33.44% 153.61% -245.72% 423.52% -255.10% 87.80% -244.42% 77.35% 4.26%
Free Cash Flow Firm Q/Q Growth		 -182.67% -170.55% 1,146.96% 108.92% -135.44% 297.68% -35.40% -27.95% -16.61% 313.85% 82.90%
Invested Capital Q/Q Growth		 1.46% -0.39% -0.65% -0.91% 1.22% -1.67% -0.09% -0.82% -0.25% -0.79% -0.67%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 43.59% 44.92% 44.62% 44.07% 41.90% 43.45% 41.01% 40.77% 39.95% 40.97% 37.97%
EBITDA Margin		 -5.53% 0.05% -1.29% -1.89% -7.58% 0.41% -3.58% -6.93% -12.13% -5.48% -16.55%
Operating Margin		 -16.56% -10.70% -12.63% -13.34% -19.56% -11.94% -15.92% -20.35% -25.56% -19.02% -30.68%
EBIT Margin		 -16.52% -10.95% -12.44% -13.34% -19.73% -11.86% -15.99% -19.85% -25.64% -19.02% -30.66%
Profit (Net Income) Margin		 -15.43% -8.91% -10.55% -11.33% -17.32% -9.21% -12.19% -16.56% -22.44% -16.36% -28.62%
Tax Burden Percent		 101.04% 95.01% 99.16% 98.03% 97.76% 93.72% 86.32% 91.33% 91.33% 88.89% 93.00%
Interest Burden Percent		 92.42% 85.64% 85.48% 86.67% 89.79% 82.85% 88.31% 91.35% 95.83% 96.74% 100.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -7.25% -4.66% -5.31% -5.45% -7.71% -4.58% -5.86% -7.16% -8.54% -6.11% -9.57%
ROIC Less NNEP Spread (ROIC-NNEP)		 -11.07% -6.43% -7.30% -7.81% -11.87% -5.78% -7.26% -10.64% -15.89% -13.49% -32.51%
Return on Net Nonoperating Assets (RNNOA)		 -2.06% -0.97% -1.13% -1.16% -1.70% -0.66% -0.84% -1.04% -1.32% -0.73% -1.21%
Return on Equity (ROE)		 -9.32% -5.63% -6.45% -6.62% -9.41% -5.24% -6.70% -8.20% -9.86% -6.84% -10.78%
Cash Return on Invested Capital (CROIC)		 -5.31% -5.33% -3.99% -4.72% -5.27% -4.13% -5.44% -5.81% -5.79% -7.23% -8.85%
Operating Return on Assets (OROA)		 -6.85% -4.36% -4.83% -5.02% -7.20% -4.10% -5.35% -6.28% -7.68% -5.37% -8.32%
Return on Assets (ROA)		 -6.40% -3.55% -4.09% -4.27% -6.32% -3.19% -4.08% -5.24% -6.72% -4.62% -7.76%
Return on Common Equity (ROCE)		 -9.32% -5.63% -6.45% -6.62% -9.41% -5.24% -6.70% -8.20% -9.86% -6.84% -10.78%
Return on Equity Simple (ROE_SIMPLE)		 -8.73% 0.00% -8.56% -8.58% -9.12% 0.00% -10.17% -11.99% -12.89% 0.00% -16.12%
Net Operating Profit after Tax (NOPAT)		 -19 -13 -15 -15 -21 -13 -17 -21 -25 -18 -28
NOPAT Margin		 -11.59% -7.49% -8.84% -9.34% -13.69% -8.36% -11.15% -14.24% -17.89% -13.31% -21.48%
Net Nonoperating Expense Percent (NNEP)		 3.82% 1.76% 1.99% 2.35% 4.16% 1.20% 1.40% 3.49% 7.35% 7.37% 22.95%
Return On Investment Capital (ROIC_SIMPLE)		 -1.36% -0.89% - - - -0.88% - - - -1.20% -
Cost of Revenue to Revenue		 56.41% 55.08% 55.38% 55.93% 58.10% 56.55% 58.99% 59.23% 60.05% 59.03% 62.03%
SG&A Expenses to Revenue		 40.59% 37.00% 39.90% 38.50% 42.11% 38.42% 40.46% 41.05% 44.85% 39.56% 49.92%
R&D to Revenue		 6.06% 4.63% 4.58% 4.79% 4.88% 4.58% 3.48% 5.11% 5.39% 4.81% 5.68%
Operating Expenses to Revenue		 60.15% 55.62% 57.25% 57.41% 61.47% 55.39% 56.93% 61.11% 65.51% 59.99% 68.65%
Earnings before Interest and Taxes (EBIT)		 -28 -19 -21 -22 -31 -18 -24 -29 -35 -26 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.30 0.09 -2.17 -3.11 -12 0.63 -5.44 -10 -17 -7.60 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.37 2.34 2.08 1.93 2.17 2.19 1.66 2.14 2.28 1.17 1.07
Price to Tangible Book Value (P/TBV)		 35.66 53.03 50.54 48.25 55.85 45.19 36.70 47.98 42.49 17.42 14.76
Price to Revenue (P/Rev)		 1.81 3.20 2.93 2.82 3.28 3.49 2.73 3.72 4.19 2.29 2.18
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.31 2.15 1.93 1.80 2.00 2.05 1.57 2.01 2.14 1.15 1.06
Enterprise Value to Revenue (EV/Rev)		 2.09 3.44 3.17 3.06 3.53 3.69 2.96 3.95 4.41 2.48 2.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 184.32 323.17 136.13 7,284.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.61 0.60 0.60 0.59 0.58 0.57 0.57 0.56 0.55 0.54 0.53
Long-Term Debt to Equity		 0.38 0.38 0.37 0.37 0.58 0.57 0.57 0.56 0.55 0.54 0.53
Financial Leverage		 0.19 0.15 0.16 0.15 0.14 0.11 0.12 0.10 0.08 0.05 0.04
Leverage Ratio		 1.79 1.80 1.79 1.78 1.76 1.76 1.75 1.74 1.73 1.71 1.70
Compound Leverage Factor		 1.65 1.54 1.53 1.55 1.58 1.46 1.55 1.59 1.65 1.66 1.71
Debt to Total Capital		 37.89% 37.49% 37.30% 37.08% 36.85% 36.37% 36.20% 35.95% 35.49% 34.91% 34.54%
Short-Term Debt to Total Capital		 14.06% 13.91% 13.84% 13.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 23.82% 23.58% 23.47% 23.33% 36.85% 36.37% 36.20% 35.95% 35.49% 34.91% 34.54%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 62.11% 62.51% 62.70% 62.92% 63.15% 63.63% 63.80% 64.05% 64.51% 65.09% 65.46%
Debt to EBITDA		 -37.41 -31.79 -32.79 -27.32 -20.09 -17.01 -13.48 -9.63 -7.89 -6.26 -5.20
Net Debt to EBITDA		 -12.69 -9.06 -9.26 -7.69 -5.74 -3.89 -3.39 -2.29 -1.74 -1.14 -0.89
Long-Term Debt to EBITDA		 -23.53 -19.99 -20.63 -17.19 -20.09 -17.01 -13.48 -9.63 -7.89 -6.26 -5.20
Debt to NOPAT		 -8.66 -8.39 -8.37 -8.09 -7.46 -7.14 -6.65 -5.86 -5.44 -4.85 -4.42
Net Debt to NOPAT		 -2.94 -2.39 -2.36 -2.28 -2.13 -1.63 -1.67 -1.39 -1.20 -0.88 -0.75
Long-Term Debt to NOPAT		 -5.45 -5.28 -5.26 -5.09 -7.46 -7.14 -6.65 -5.86 -5.44 -4.85 -4.42
Altman Z-Score		 1.30 2.03 1.85 1.76 2.12 2.14 1.74 2.10 2.25 1.41 1.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.05 1.98 1.99 2.01 7.48 6.20 6.32 6.16 6.75 6.73 7.10
Quick Ratio		 1.82 1.78 1.82 1.84 6.85 5.67 5.76 5.64 6.20 6.20 6.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -4.96 7.02 0.56 -6.32 18 4.48 6.94 9.63 12 -5.40
Operating Cash Flow to CapEx		 -562.82% 84.49% 85.62% 106.22% -464.01% 252.01% -128.61% -20.66% -127.85% -81.27% -207.45%
Free Cash Flow to Firm to Interest Expense		 -8.66 -3.05 4.28 0.34 -3.75 10.60 2.66 3.89 5.48 2.21 -38.84
Operating Cash Flow to Interest Expense		 -15.65 6.03 5.63 8.34 -15.38 10.58 -3.26 -0.87 -7.22 -0.71 -117.06
Operating Cash Flow Less CapEx to Interest Expense		 -18.43 -1.11 -0.95 0.49 -18.69 6.38 -5.80 -5.07 -12.87 -1.58 -173.50
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.41 0.40 0.39 0.38 0.36 0.35 0.33 0.32 0.30 0.28 0.27
Accounts Receivable Turnover		 4.61 4.69 4.54 4.62 4.71 4.72 4.70 4.66 4.61 4.40 4.58
Inventory Turnover		 14.95 14.56 14.99 14.97 15.88 14.33 14.25 14.15 13.48 13.50 14.04
Fixed Asset Turnover		 7.58 7.10 6.87 6.54 6.40 6.08 5.71 5.22 5.00 4.81 4.64
Accounts Payable Turnover		 21.68 17.67 21.82 20.54 17.32 16.99 22.34 19.06 15.06 16.75 15.17
Days Sales Outstanding (DSO)		 79.12 77.85 80.49 79.02 77.44 77.41 77.67 78.31 79.11 83.01 79.71
Days Inventory Outstanding (DIO)		 24.41 25.08 24.34 24.39 22.98 25.47 25.61 25.79 27.08 27.03 25.99
Days Payable Outstanding (DPO)		 16.84 20.66 16.73 17.77 21.08 21.48 16.34 19.15 24.23 21.79 24.06
Cash Conversion Cycle (CCC)		 86.69 82.26 88.10 85.63 79.34 81.40 86.95 84.95 81.96 88.25 81.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,072 1,057 1,061 1,068 1,078 1,065 1,083 1,084 1,093 1,095 1,104
Invested Capital Turnover		 0.63 0.62 0.60 0.58 0.56 0.55 0.53 0.50 0.48 0.46 0.45
Increase / (Decrease) in Invested Capital		 -5.47 -7.93 -22 -16 -15 -31 -21 -28 -34 -30 -22
Enterprise Value (EV)		 1,403 2,270 2,043 1,923 2,158 2,185 1,704 2,178 2,337 1,264 1,174
Market Capitalization		 1,219 2,115 1,890 1,771 2,004 2,062 1,569 2,050 2,219 1,167 1,083
Book Value per Share		 $6.91 $7.03 $7.09 $7.17 $7.32 $7.39 $7.43 $7.50 $7.65 $7.90 $8.05
Tangible Book Value per Share		 $0.27 $0.31 $0.29 $0.29 $0.28 $0.36 $0.34 $0.34 $0.41 $0.53 $0.58
Total Capital		 1,430 1,443 1,449 1,456 1,462 1,480 1,485 1,493 1,510 1,533 1,548
Total Debt		 542 541 540 540 539 538 537 537 536 535 535
Total Long-Term Debt		 341 340 340 340 539 538 537 537 536 535 535
Net Debt		 184 154 153 152 154 123 135 127 118 97 91
Capital Expenditures (CapEx)		 4.50 12 11 13 5.59 7.06 4.27 7.49 9.93 4.53 7.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 137 109 106 106 112 85 92 81 80 77 75
Debt-free Net Working Capital (DFNWC)		 495 496 494 494 497 501 494 490 498 515 518
Net Working Capital (NWC)		 294 295 294 294 497 501 494 490 498 515 518
Net Nonoperating Expense (NNE)		 6.45 2.44 2.86 3.28 5.66 1.32 1.58 3.41 6.24 4.22 9.20
Net Nonoperating Obligations (NNO)		 184 154 153 152 154 123 135 127 118 97 91
Total Depreciation and Amortization (D&A)		 18 19 19 19 19 19 19 19 19 19 18
Debt-free, Cash-free Net Working Capital to Revenue		 20.42% 16.46% 16.53% 16.95% 18.40% 14.42% 15.96% 14.60% 15.19% 15.18% 15.06%
Debt-free Net Working Capital to Revenue		 73.68% 75.02% 76.73% 78.68% 81.42% 84.60% 85.95% 88.81% 94.08% 101.10% 104.35%
Net Working Capital to Revenue		 43.76% 44.63% 45.62% 46.84% 81.42% 84.60% 85.95% 88.81% 94.08% 101.10% 104.35%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) $0.00 ($0.14) $0.00 ($0.21) $0.00 ($0.15) ($0.19) ($0.25) ($0.18) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 127.38M 126.66M 126.95M 126.41M 126.11M 125.50M 125.69M 125.36M 125.03M 124.22M 124.43M
Adjusted Diluted Earnings per Share		 ($0.20) $0.00 ($0.14) $0.00 ($0.21) $0.00 ($0.15) ($0.19) ($0.25) ($0.18) ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 127.38M 126.66M 126.95M 126.41M 126.11M 125.50M 125.69M 125.36M 125.03M 124.22M 124.43M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 128.69M 128.46M 128.36M 128.16M 127.71M 127.61M 127.47M 127.55M 127.58M 127.46M 126.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -12 -14 -14 -20 -12 -15 -19 -21 -15 -28
Normalized NOPAT Margin		 -11.59% -6.79% -8.42% -8.68% -12.62% -7.82% -10.17% -12.78% -15.50% -11.04% -21.48%
Pre Tax Income Margin		 -15.27% -9.38% -10.64% -11.56% -17.72% -9.83% -14.12% -18.13% -24.57% -18.40% -30.77%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -17.16 -11.60 -12.72 -13.17 -18.30 -10.98 -14.42 -16.35 -20.03 -5.06 -284.06
NOPAT to Interest Expense		 -12.04 -7.93 -9.04 -9.22 -12.70 -7.73 -10.05 -11.73 -13.97 -3.54 -198.97
EBIT Less CapEx to Interest Expense		 -19.94 -18.74 -19.29 -21.02 -21.61 -15.17 -16.95 -20.55 -25.68 -5.93 -340.50
NOPAT Less CapEx to Interest Expense		 -14.82 -15.07 -15.61 -17.07 -16.01 -11.93 -12.59 -15.93 -19.62 -4.41 -255.40
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About NeoGenomics' Financials

When does NeoGenomics's fiscal year end?

According to the most recent income statement we have on file, NeoGenomics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has NeoGenomics' net income changed over the last 10 years?

NeoGenomics' net income appears to be on an upward trend, with a most recent value of -$78.73 million in 2024, falling from $1.13 million in 2014. The previous period was -$87.97 million in 2023. See where experts think NeoGenomics is headed by visiting NeoGenomics' forecast page.

What is NeoGenomics's operating income?
NeoGenomics's total operating income in 2024 was -$92.11 million, based on the following breakdown:
  • Total Gross Profit: $290.10 million
  • Total Operating Expenses: $382.21 million
How has NeoGenomics revenue changed over the last 10 years?

Over the last 10 years, NeoGenomics' total revenue changed from $87.07 million in 2014 to $660.57 million in 2024, a change of 658.7%.

How much debt does NeoGenomics have?

NeoGenomics' total liabilities were at $735.70 million at the end of 2024, a 0.5% decrease from 2023, and a 3,453.9% increase since 2014.

How much cash does NeoGenomics have?

In the past 10 years, NeoGenomics' cash and equivalents has ranged from $9.81 million in 2018 to $367.01 million in 2024, and is currently $367.01 million as of their latest financial filing in 2024.

How has NeoGenomics' book value per share changed over the last 10 years?

Over the last 10 years, NeoGenomics' book value per share changed from 1.01 in 2014 to 7.03 in 2024, a change of 597.9%.


Related Companies

This page (NASDAQ:NEO) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored